Patanjali was the first Indian company to publish a research paper on the new Covid-19 drug approved by DCGI: Read details

On May 8, Defence Research and Development Organisation (DRDO) announced that it got approval for an anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) from the Drugs Controller General of India (DCGI). The Covid-19 application of the drug has been developed by a lab of Defence Research and Development Organisation (DRDO), Institute of Nuclear Medicine and Allied Sciences (INMAS) and Dr Reddy’s Laboratories (DRL), Hyderabad. The drug was originally developed for the treatment of cancer.

According to the press released by DRDO, the results of the clinical trials showed the molecule helps in quicker recovery of hospitalised patients and reduces the requirement of supplemental oxygen. The Covid-19 patients who were treated with 2-DG showed a higher proportion of negative conversions. Experts suggested that the drug will be beneficial for the people suffering from Covid-19.

Although Covid-19 and Cancer are completely different diseases, the same drug has been found effective because of the similarities between the virus and cancer cells. But the virus and cancer cells replicate very fast, which means they consume lots of energy. Glucose is the main source of energy in living beings, and thus both of them use glucose very fast to survive and replicate. Therefore, these cells also consume a high amount of the drug 2-deoxy-D-glucose. As the drug and inhibits both glycolysis as well as glycosylation, it hampers the growth of the virus.

History of the drug trials by DRDO

In April 2020, INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad. The results showed it works effectively against the SARS-CoV-2 virus and prevents viral growth. Based on the results, DCGI’s Central Drugs Standard Control Organization (CDSCO) gave permission for Phase-II clinical trials of the drug in May 2020.

DRDO and DRL found that it was safe for Covid-19 patients and improved the recovery rate. Phase IIa was conducted in six hospitals, while Phase IIb (dose-ranging) clinical trial was conducted in 11 hospitals across the country. A total of 110 patients were treated with the drug. The patients treated with 2-DG showed faster symptomatic cure compared to Standard of Care (SoC) on various endpoints. There was a significant favourable trend 2.5-days difference in terms of median time to achieving normalisation of specific vital signs parameters compared to SoC.

In November 2020, DCGI gave permission for the Phase-III clinical trials, which was conducted on 220 patients. It ended in March 2021. Detailed data of the Phase-III study was presented to DCGI, which further granted permission for emergency use of the drug as an adjunct therapy in moderate to severe COVID-19 patients.

Research paper published by Patanjali on 2-DG molecule

Before DRDO conducted trials on the drug, scientists and experts from Patanjali Ayurved Ltd, Jain Vishwa Bharti Institute, and Saveetha Institute of Medical and Technical Sciences had published a paper in March 2020 on the possible use of the molecule for Covid-19. The paper titled “Glucose antimetabolite 2-Deoxy-D-Glucose and its derivative as promising candidates for tackling COVID-19: Insights derived from in silico docking and molecular simulations” talked about the research done by the institute to understand 2-DG’s effect on the SARK-CoV-2 virus that causes Covid-19. Patanjali was the first Indian company to do a study on the drug just when the pandemic had just hit the world.

2-deoxy-D-glucose (2-DG), which is a radio-chemo-modifier drug used for optimising cancer therapy, and one of its derivatives (1, 3, 4, 6-Tetra-O-acetyl-2-deoxy-D-glucopyranose) were investigated by conducting ligand-receptor docking. Binding pose depictions of ligands and viral receptors were assessed by employing molecular dynamics analysis. The researchers used Molinspiration and Toxicity Estimation Software tools to determine the drug likeliness, bioactivity indices and ADMETox values and found that 2-DG can efficiently inactivate the viral receptors leading to incapacitation of the SARS-CoV-2 virus.

Graphics from research paper published by Patanjali

The paper suggested, “The present in silico study supports the potential benefits of using 2-DG and its glucopyranose derivative as repurposed drugs/prodrugs for mitigating the novel COVID-19 infection. Since both these moieties present no signs of serious toxicity, further empirical studies on model systems and human clinical trials to ascertain effective dose-response are warranted and should be urgently initiated.”

An in silico study refers to a study done on Computer, and it is widely used in biology, medicine and other experimental sciences. In the Patanjali study, 3D models of the SARS-CoV-2 virus and the molecules of the study drug were studied in various software programs to see how the drug works on the virus.

The researchers had obtained the crystal structures of SARS-CoV-2 spike glycoprotein, viral nuclease and protease from RCSB Protein Data Bank, obtained the structure of 2-deoxy-D-glucose and 2-DG derivative from PubChem database, and 3D structures of all of them were introduced in Argus Lab (4.0.1) program.

Graphics from research paper published by Patanjali

The researchers had obtained the crystal structures of SARS-CoV-2 spike glycoprotein, viral nuclease and protease from RCSB Protein Data Bank, and 3D structures of all of them were introduced in Argus Lab (4.0.1) proram.

After converting the hydrogenated ligand molecules into pdb format using Open Babel (2.4) interface, online tool DoG Site Scorer was used to predict the possible binding sites in the 3D structure of spike glycoprotein, viral nuclease and viral main protease. 

Hex Cuda 8.0.0 software was used for docking analysis of pdb structures of the study molecules with the viral receptors.  In this study, the binding free energy of the receptors to ligands was calculated using the GROMACS tool. After that, Molinspiration software was used to analyse molecular descriptors and bioactivity scores of the ligands and standard chemotherapeutic agents.

Graphics from research paper published by Patanjali

Following the analysis of the results of the study, the researchers had concluded that 2-DG may considerably reduce the infectivity and virulence of nCOVID-19 by inhibiting both the entry and the replication of the virus inside the host cells. They had suggested further study on model systems infected with nCOVID-19 to verify this possibility before conducting human trials.

Experts mentioned Patanjali’s study while thanking DRDO

Several experts, including JNU’s Anand Ranganathan, mentioned the research done by Patanjali in March 2020.

Ranganathan said, “Congrats to DRDO for EUA for 2deoxy-D-glucose, 2DG. An anti-cancer drug, its MoA might be inhibiting glycolysis in virus-infected cells. Also, appreciate Yogrishi Ramdev’s Patanjali for first suggesting the use of 2DG, although their hypothesis was that 2DG directly attacks the virus.”

Dr Amit Thadhani said, “Researchers at Patanjali were the first to publish a paper hypothesising the potential benefit of glucose analogue in COVID19 treatment. But Dr Reddy’s brings it into the market and gets the emergency approval.”

Drug to hit the market soon

The drug will be available soon for the Covid-19 patients, and it could be taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique. While talking to Aaj Tak, Anant Narayan Bhatt, scientist DRDO, said the trial was conducted on moderate and severe patients, but the drug should be effective for mild patients as well.
OpIndia Staff: Staff reporter at OpIndia